ARGX News and Press, argenx SE From 06/28/24

2024-06-28 10:20:00 ET Summary Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S. who are currently not well controlled on other dr...

2024-06-26 07:00:04 ET Douglas Tsao from H.C. Wainwright issued a price target of $490.00 for ARGX on 2024-06-26 06:09:00. The adjusted price target was set to $490.00. At the time of the announcement, ARGX was trading at $451.55. The overall price target consensus is at...

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...

2024-06-24 16:00:10 ET Joon Lee from Truist Financial issued a price target of $480.00 for ARGX on 2024-06-24 14:06:00. The adjusted price target was set to $480.00. At the time of the announcement, ARGX was trading at $441.155. The overall price target consensus is at $...

2024-06-24 15:30:02 ET Citigroup analyst issues BUY recommendation for ARGX on June 24, 2024 02:08PM ET. The previous analyst recommendation was Buy. ARGX was trading at $441.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2024-06-24 11:30:02 ET Scotiabank analyst issues SECTOR PERFORM recommendation for ARGX on June 24, 2024 09:32AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $432.19 at issue of the analyst recommendation. The overall analyst consensus ...

2024-06-24 07:00:11 ET Derek Archila from Wells Fargo issued a price target of $542.00 for ARGX on 2024-06-24 06:01:00. The adjusted price target was set to $542.00. At the time of the announcement, ARGX was trading at $394.47. The overall price target consensus is at $3...

2024-06-21 17:11:38 ET More on Argenx SE argenx SE (ARGX) Q1 2024 Earnings Call Transcript argenx: Innovation Over Losses In Autoimmune Arena argenx misses top-line and bottom-line estimates; updates FY24 outlook Argenx SE Q1 2024 Earnings Preview See...

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART®...

2024-06-19 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...